Exhibit 99.1

Graphic

FOR IMMEDIATE RELEASE

Contact:

Chris Lewis

Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Glaukos Corporation Announces Second Quarter 2020 Financial Results

San Clemente, CA – August 6, 2020 –

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2020. Key highlights include:

·

Q2 2020 net sales of $31.6 million, compared to $58.6 million in Q2 2019.

·

Glaucoma Q2 2020 net sales of $24.9 million, compared to $58.6 million in Q2 2019.

·

Corneal Health Q2 2020 net sales of $6.6 million.

“I am extremely proud of the actions, focus and accomplishments of our employees, who have remained dedicated to advancing our key strategic objectives while navigating the unique challenges associated with the COVID-19 pandemic,” said Thomas Burns, Glaukos president and chief executive officer. “We are encouraged with the initial return of elective procedures around the world and remain well-positioned to provide our essential ophthalmic therapies to our customers and their patients during the ongoing recovery period. I am confident the longer-term fundamental prospects of our business remain strong as we advance our mission to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.”

Second Quarter 2020 Financial Results

Net sales decreased 46% in the second quarter of 2020 to $31.6 million, compared to $58.6 million in the same period in 2019. The decrease was driven primarily by disruptions associated with COVID-19, partially offset by contribution from the Avedro acquisition.

Gross margin for the second quarter of 2020 was approximately 31%, compared to approximately 87% in the same period in 2019. Non-GAAP gross margin for the second quarter of 2020 was approximately 78%, compared to approximately 87% in the same period in 2019.

Selling, general and administrative (SG&A) expenses for the second quarter of 2020 rose 1% to $38.1 million, compared to $37.7 million in the same period in 2019. Non-GAAP SG&A expenses for the second quarter of 2020 rose 2% to $33.6 million, compared to $33.0 million in the same period in 2019.

Research and development (R&D) expenses in the second quarter of 2020 rose 11% to $19.0 million, compared to $17.1 million in the same period in 2019. Non-GAAP R&D expenses for the second quarter of 2020 rose 9% to $18.6 million, compared to $17.1 million in the same period in 2019.

Loss from operations in the second quarter of 2020 was $47.2 million, compared to an operating loss of $6.2 million in the second quarter of 2019. Non-GAAP loss from operations in the second quarter of 2020 was $27.6 million, compared to non-GAAP operating income of $0.7 million in the second quarter of 2019.

1


The following information was filed by Glaukos Corp (GKOS) on Thursday, August 6, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Glaukos Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Glaukos Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account